NewAmsterdam Pharma Company N.V. (NAMS)
(Delayed Data from NSDQ)
$19.29 USD
-0.30 (-1.53%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $19.33 +0.04 (0.21%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
NAMS 19.29 -0.30(-1.53%)
Will NAMS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NAMS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NAMS
NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up
After Plunging -16.36% in 4 Weeks, Here's Why the Trend Might Reverse for NewAmsterdam Pharma Company N.V. (NAMS)
NAMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for NAMS
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Buy Rating on NewAmsterdam Pharma: High Hopes for Obicetrapib’s Phase 3 Trials
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
NewAmsterdam Pharma Secures Key Patent, Eyes Commercialization